These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7371367)

  • 1. Bioavailability and kinetics of maprotiline.
    Alkalay D; Wagner WE; Carlsen S; Khemani L; Volk J; Bartlett MF; LeSher A
    Clin Pharmacol Ther; 1980 May; 27(5):697-703. PubMed ID: 7371367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.
    Maguire KP; Norman TR; Burrows GD; Scoggins BA
    Eur J Clin Pharmacol; 1980 Oct; 18(3):249-54. PubMed ID: 7439244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly.
    Hrdina PD; Rovei V; Henry JF; Hervy MP; Gomeni R; Forette F; Morselli PL
    Psychopharmacology (Berl); 1980; 70(1):29-34. PubMed ID: 6775331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explicit solution to pharmacokinetic first-order rate constants of maprotilin.
    Shah BK; Kline NS; Angst J
    Int Pharmacopsychiatry; 1974; 9(4):230-4. PubMed ID: 4457498
    [No Abstract]   [Full Text] [Related]  

  • 5. Selected ion monitoring assay for the antidepressant maprotiline.
    Alkalay D; Carlsen S; Khemani L; Bartlett MF
    Biomed Mass Spectrom; 1979 Oct; 6(10):435-8. PubMed ID: 526561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the antidepressants maprotiline and amoxapine, and their metabolites, in plasma by liquid chromatography.
    Wong SH; Waugh SW
    Clin Chem; 1983 Feb; 29(2):314-8. PubMed ID: 6821936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic fate of [14C]oxaprotiline.HCl in man. I. Disposition and preliminary pharmacokinetics.
    Dieterle W; Faigle JW; Imhof P; Sulc M; Wagner J
    Xenobiotica; 1984 Apr; 14(4):303-10. PubMed ID: 6464500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product.
    Blume HH; Wedemeyer RS; Donath F; Roscher K; Elvert G; Wagner D; Bley O; Vuia A; Todorova-Sanjari M; Villalobos R; Schug B
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):335-44. PubMed ID: 25669614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis.
    Lynn K; Braithwaite R; Dawling S; Rosser R
    Eur J Clin Pharmacol; 1981 Jan; 19(1):73-7. PubMed ID: 7461027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin bioavailability: formulations and rates of infusions.
    Marcus FI; Dickerson J; Pippin S; Stafford M; Bressler R
    Clin Pharmacol Ther; 1976 Sep; 20(3):253-9. PubMed ID: 954346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states.
    Pinder RM; Brogden RN; Speight TM; Avery GS
    Drugs; 1977 May; 13(5):321-52. PubMed ID: 326531
    [No Abstract]   [Full Text] [Related]  

  • 13. [Blood concentrations of maprotiline in depressive patients].
    Rouillon F; Sioufi A; Serrurier D; Mizon JP; Plaquet R; Richard JB; Riche C; Bourin M; Kergueris MF; Besançon G
    Encephale; 1988; 14(4):299-305. PubMed ID: 3058453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of orally administered propiram fumarate in humans.
    Korduba CA; Veals J; Radwanski E; Symchowicz S; Chung M
    J Pharm Sci; 1981 May; 70(5):521-3. PubMed ID: 7241356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The concentrations of amitriptyline, maprotiline and their demethylated metabolites, nortriptyline and desmethylmaprotiline, in rat plasma and brain].
    Yufu N
    Seishin Shinkeigaku Zasshi; 1987; 89(1):22-42. PubMed ID: 3615663
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of propranolol on maprotiline clearance.
    Tollefson G; Lesar T
    Am J Psychiatry; 1984 Jan; 141(1):148-9. PubMed ID: 6691445
    [No Abstract]   [Full Text] [Related]  

  • 17. The metabolic fate of 14C-oxaprotiline X HCl in man. III. Stereospecific disposition.
    Dieterle W; Faigle JW; Küng W; Theobald W
    Biopharm Drug Dispos; 1984; 5(4):377-86. PubMed ID: 6525444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.
    Coupez R; Straetemans R; Sehgal G; Stockis A; Lu ZS
    J Clin Pharmacol; 2003 Dec; 43(12):1370-6. PubMed ID: 14615473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLC-mass spectrometric determination of maprotiline and its major metabolite using stable isotope-labeled analog as internal standard.
    Jindal SP; Lutz T; Vestergaard P
    J Pharm Sci; 1980 Jun; 69(6):684-7. PubMed ID: 7205583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of ergoloid mesylates liquid capsule.
    Schran HF
    Clin Ther; 1985; 8(1):71-5. PubMed ID: 3833371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.